213 related articles for article (PubMed ID: 26844985)
1. Experimental treatment strategies in primary cutaneous T-cell lymphomas.
Rozati S; Kim YH
Curr Opin Oncol; 2016 Mar; 28(2):166-71. PubMed ID: 26844985
[TBL] [Abstract][Full Text] [Related]
2. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
Welborn M; Duvic M
Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for the treatment of cutaneous T-cell lymphoma.
Cheng M; Zain J; Rosen ST; Querfeld C
Expert Opin Emerg Drugs; 2022 Mar; 27(1):45-54. PubMed ID: 35235473
[TBL] [Abstract][Full Text] [Related]
5. Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.
Saulite I; Guenova E; Hoetzenecker W
Curr Probl Dermatol; 2018; 53():70-81. PubMed ID: 29131039
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies.
Geskin LJ
Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in primary cutaneous T-cell lymphoma.
DeSimone JA; Sodha P; Ignatova D; Dummer R; Cozzio A; Guenova E
Curr Opin Oncol; 2015 Mar; 27(2):128-33. PubMed ID: 25594623
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
11. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
Chung CG; Poligone B
Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791
[No Abstract] [Full Text] [Related]
16. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
17. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
18. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
[No Abstract] [Full Text] [Related]
19. New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ
Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
[TBL] [Abstract][Full Text] [Related]
20. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
Guenova E; Hoetzenecker W; Rozati S; Levesque MP; Dummer R; Cozzio A
Expert Opin Investig Drugs; 2014 Apr; 23(4):457-67. PubMed ID: 24397291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]